[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Skye Bioscience Inc (SKYE)

Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,291
  • Shares Outstanding, K 35,144
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,920 K
  • EBIT $ -59 M
  • EBITDA $ -58 M
  • 60-Month Beta 2.97
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.11
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.44
  • Most Recent Earnings $-0.32 on 05/11/26
  • Next Earnings Date 08/13/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 554.82% (+5.83%)
  • Historical Volatility 72.12%
  • IV Percentile 75%
  • IV Rank 42.11%
  • IV High 1,135.22% on 03/17/26
  • IV Low 132.62% on 10/13/25
  • Expected Move (DTE 7) 1.6405 (303.23%)
  • Put/Call Vol Ratio 188.00
  • Today's Volume 189
  • Volume Avg (30-Day) 151
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 5,654
  • Open Int (30-Day) 5,139
  • Expected Range 0.0000 to 2.1815

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.29
  • Number of Estimates 3
  • High Estimate $-0.15
  • Low Estimate $-0.36
  • Prior Year $-0.44
  • Growth Rate Est. (year over year) +34.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2760 +96.01%
on 08/06/26
0.6960 -22.27%
on 07/22/26
-0.1210 (-18.28%)
since 07/13/26
3-Month
0.2760 +96.01%
on 08/06/26
0.9198 -41.18%
on 05/14/26
-0.2787 (-34.00%)
since 05/13/26
52-Week
0.2760 +96.01%
on 08/06/26
4.9902 -89.16%
on 10/03/25
-2.5990 (-82.77%)
since 08/13/25

Most Recent Stories

More News
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic...

SKYE : 0.5410 (-1.44%)
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 SAN DIEGO, May ...

SKYE : 0.5410 (-1.44%)
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 Engaged Lilly Catalyze360...

SKYE : 0.5410 (-1.44%)
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

SKYE : 0.5410 (-1.44%)
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

SKYE : 0.5410 (-1.44%)
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts; Received written FDA Type C meeting minutes;...

SKYE : 0.5410 (-1.44%)
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and...

SKYE : 0.5410 (-1.44%)
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab...

SKYE : 0.5410 (-1.44%)
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

SKYE : 0.5410 (-1.44%)
Skye Bioscience to Present Poster at Keystone Obesity Conference

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

SKYE : 0.5410 (-1.44%)

Business Summary

Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif.

See More

Key Turning Points

3rd Resistance Point 0.5663
2nd Resistance Point 0.5581
1st Resistance Point 0.5496
Last Price 0.5410
1st Support Level 0.5329
2nd Support Level 0.5247
3rd Support Level 0.5162

See More

52-Week High 4.9902
Fibonacci 61.8% 3.1894
Fibonacci 50% 2.6331
Fibonacci 38.2% 2.0768
Last Price 0.5410
52-Week Low 0.2760

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.